Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct:65:67-76.
doi: 10.1016/j.breast.2022.06.007. Epub 2022 Jul 7.

Anthracyclines in the treatment of early breast cancer friend or foe?

Ana Tecic Vuger  1 , Katsuki Tiscoski  2 , Thiago Apolinario  3 , Fatima Cardoso  4
Affiliations
Review

Anthracyclines in the treatment of early breast cancer friend or foe?

Ana Tecic Vuger et al. Breast. 2022 Oct.

Abstract

Standard chemotherapy for early breast cancer consists generally of an anthracycline - taxane - based regimen, preferably in sequence. Anthracyclines are among the most active cytotoxic drugs against breast cancer. Nevertheless, benefits attained by the use of the more potent anthracycline schedules must be balanced against increased short - and long - term toxicity, and treatment options must be individualized for each patient. Authors review available data regarding anthracycline efficacy and toxicity in the early breast cancer setting and the potential directions for future research.

Keywords: Anthracyclines; Early breast cancer; Efficacy; Toxicity; Treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Breast cancer mortality data adapted from EBCTCG meta-analysis.
Fig. 2
Fig. 2
Trials comparing anthracyclines and non-anthracyclines based regimens.
See this image and copyright information in PMC

References

    1. Beretta G.L., Zunino F. Molecular mechanisms of anthracycline activity. Top Curr Chem. 2007;283(October 2007):1–19. doi: 10.1007/128_2007_3. - DOI - PubMed
    1. Young C., Ozols R., Myers C. The anthracycline antineoplastic drugs. N Engl J Med. 1981;305(3):139–153. doi: 10.1056/NEJM198107163050305. - DOI - PubMed
    1. Fisher B., Redmond C., Wickerham D.L., Bowman D., Schipper H., Wolmark N., et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol. 1989;7(5):572–582. doi: 10.1200/JCO.1989.7.5.572. - DOI - PubMed
    1. Fisher B., Brown A.M., Dimitrov N.V., Poisson R., Redmond C., Margolese R.G., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 Months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from t. J Clin Oncol. 1990;8(9):1483–1496. doi: 10.1200/JCO.1990.8.9.1483. - DOI - PubMed
    1. Albain K., Anderson S., Arriagada R., Barlow W., Bergh J., Bliss J., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012;379:432–444. doi: 10.1016/S0140-6736(11)61625-5. - DOI - PMC - PubMed

MeSH terms